Why Immunovant Stock Dropped Today

Shares of clinical-stage biopharmaceutical company Immunovant (NASDAQ: IMVT) plunged by 27.2% on Tuesday following the company's release of its financial results for the third quarter of its fiscal year 2021 that ended on Dec. 31.

There wasn't a lot of new or groundbreaking information in Immunovant's quarterly update. The company does not have any products on the market, and it does not generate any revenue. The drugmaker recorded a net loss of $31.8 million on the bottom line, or a loss of $0.32 on a per-share basis. On average, analysts expected the company to record a net loss per share of $0.26.

Could the bottom-line miss be the reason why Immunovant's stock lost altitude today? That seems unlikely: Investors don't care too much about the revenue and earnings of clinical-stage biopharmaceutical companies. Rather, regulatory updates and information regarding the progress of clinical trials are much more critical.

Source Fool.com